Deborah Saraggi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deborah Saraggi has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Matteo Fassan
Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, 35128 Padua, Italy
11 shared publications Massimo Rugge
General Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35121 Italy
7 shared publicationsVincenza Guzzardo
General Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, 35121 Italy
7 shared publications- Fabio Farinati
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
5 shared publications - Massimo Rugge
Department of Medicine DIMED—Pathology Unit University of Padova, 35100 Padova, Italy
4 shared publications - Nicola Valeri
Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom
4 shared publications
Latest Publications
- 1 March 2019
- Published by Elsevier in Human Pathology
- Vol. 85, 251-259
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma
- 1 March 2019
- Published by Elsevier in Human Pathology
- Vol. 85, 251-259
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma
- 1 October 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 79 (4) , 728-735
Prevalence of ALK gene alterations among the spectrum of plexiform spitzoid lesions
- 1 October 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 79 (4) , 728-735
Prevalence of ALK gene alterations among the spectrum of plexiform spitzoid lesions
- 1 August 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36 (8) , 1772-1774
A 10-year history of secondary hypertension
- 1 August 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36 (8) , 1772-1774
A 10-year history of secondary hypertension
- 1 June 2018
- Published by Elsevier in Pathology - Research and Practice
- Vol. 214 (6) , 835-839
MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions
- 1 June 2018
- Published by Elsevier in Pathology - Research and Practice
- Vol. 214 (6) , 835-839
MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions
- 29 June 2017
- Published by Wiley in Histopathology
- Vol. 71 (3) , 470-474
PD‐L1 overexpression in ampulla of Vater carcinoma and its pre‐invasive lesions
Aims: PD‐1/PD‐L1 checkpoint immunotherapy has been proposed recently as a promising treatment in relapsed/refractory disease, used eventually in combination with traditional chemotherapy in different cancer settings. To date, no data are available concerning PD‐L1 expression in ampulla of Vater carcinoma and its pre‐invasive lesions.Methods and results: We assessed the immunohistochemical expression of PD‐L1 in a series of 26 ampullary adenocarcinomas, 50 ampullary dysplastic lesions and 10 normal duodenal mucosa samples. Moreover, in all cases DNA mismatch repair proteins status was investigated. PD‐L1 was expressed in seven of 26 (26.9%) invasive carcinomas and three of 50 (6.0%) dysplastic samples. Most of the PD‐L1‐positive tumours (seven of 10) were intestinal‐type and poorly differentiated (G3). The number of PD‐L1‐positive stromal lymphoid cells was significantly higher in dysplastic and invasive lesions than in the normal samples (P = 0.011). Nineteen dysplastic lesions and eight invasive carcinomas did not show any evident epithelial or stromal PD‐L1 expression. Four of the carcinomas were mismatch repair‐deficient and two of these were PD‐L1‐positive. Furthermore, mismatch repair‐deficient lesions showed a significantly higher average of PD‐L1‐positive stromal lymphoid cells than those of neoplastic PD‐L1‐negative samples (62.8 versus 21.6; P < 0.001).Conclusions: The present results suggest a role of the PD‐1/PD‐L1 axis in ampullary adenocarcinomas, and therefore this may also prompt consideration of checkpoint immunotherapy as a novel promising treatment for these tumours.
- 29 June 2017
- Published by Wiley in Histopathology
- Vol. 71 (3) , 470-474
PD‐L1 overexpression in ampulla of Vater carcinoma and its pre‐invasive lesions
Aims: PD‐1/PD‐L1 checkpoint immunotherapy has been proposed recently as a promising treatment in relapsed/refractory disease, used eventually in combination with traditional chemotherapy in different cancer settings. To date, no data are available concerning PD‐L1 expression in ampulla of Vater carcinoma and its pre‐invasive lesions.Methods and results: We assessed the immunohistochemical expression of PD‐L1 in a series of 26 ampullary adenocarcinomas, 50 ampullary dysplastic lesions and 10 normal duodenal mucosa samples. Moreover, in all cases DNA mismatch repair proteins status was investigated. PD‐L1 was expressed in seven of 26 (26.9%) invasive carcinomas and three of 50 (6.0%) dysplastic samples. Most of the PD‐L1‐positive tumours (seven of 10) were intestinal‐type and poorly differentiated (G3). The number of PD‐L1‐positive stromal lymphoid cells was significantly higher in dysplastic and invasive lesions than in the normal samples (P = 0.011). Nineteen dysplastic lesions and eight invasive carcinomas did not show any evident epithelial or stromal PD‐L1 expression. Four of the carcinomas were mismatch repair‐deficient and two of these were PD‐L1‐positive. Furthermore, mismatch repair‐deficient lesions showed a significantly higher average of PD‐L1‐positive stromal lymphoid cells than those of neoplastic PD‐L1‐negative samples (62.8 versus 21.6; P < 0.001).Conclusions: The present results suggest a role of the PD‐1/PD‐L1 axis in ampullary adenocarcinomas, and therefore this may also prompt consideration of checkpoint immunotherapy as a novel promising treatment for these tumours.
- Open Access
- 17 April 2017
- Published by Wiley in British Journal of Haematology
- Vol. 178 (1) , 81-93
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells
Summary: Cortactin (CTTN) is a substrate of the Src kinase Lyn that is known to play an actin cytoskeletal regulatory role involved in cell migration and cancer progression following its phosphorylation at Y421. We recently demonstrated that Cortactin is overexpressed in patients with chronic lymphocytic leukaemia (CLL). This work was aimed at defining the functional role of Cortactin in these patients. We found that Cortactin is variably expressed in CLL patients both in the peripheral blood and lymph nodes and that its expression correlates with the release of matrix metalloproteinase 9 (MMP‐9) and the motility of neoplastic cells. Cortactin knockdown, by siRNA, induced a reduction in MMP‐9 release as well as a decrease of migration capability of leukaemic B cells in vitro, also after chemotactic stimulus. Furthermore, Cortactin phosphorylation was lowered by the Src kinase‐inhibitor PP2 with a consequent decrease of MMP‐9 release in culture medium. An impaired migration, as compared to control experiments without Cortactin knockdown, was observed following CXCL12 triggering. Reduced Cortactin expression and phosphorylation were also detected both in vivo and in vitro after treatment with Ibrutinib, a Btk inhibitor. Our results highlight the role of Cortactin in CLL as a check‐point molecule between the BCR and CXCR4 signalling pathways.
- 17 April 2017
- Published by Wiley in British Journal of Haematology
- Vol. 178 (1) , 81-93
Open AccessCortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells
Summary: Cortactin (CTTN) is a substrate of the Src kinase Lyn that is known to play an actin cytoskeletal regulatory role involved in cell migration and cancer progression following its phosphorylation at Y421. We recently demonstrated that Cortactin is overexpressed in patients with chronic lymphocytic leukaemia (CLL). This work was aimed at defining the functional role of Cortactin in these patients. We found that Cortactin is variably expressed in CLL patients both in the peripheral blood and lymph nodes and that its expression correlates with the release of matrix metalloproteinase 9 (MMP‐9) and the motility of neoplastic cells. Cortactin knockdown, by siRNA, induced a reduction in MMP‐9 release as well as a decrease of migration capability of leukaemic B cells in vitro, also after chemotactic stimulus. Furthermore, Cortactin phosphorylation was lowered by the Src kinase‐inhibitor PP2 with a consequent decrease of MMP‐9 release in culture medium. An impaired migration, as compared to control experiments without Cortactin knockdown, was observed following CXCL12 triggering. Reduced Cortactin expression and phosphorylation were also detected both in vivo and in vitro after treatment with Ibrutinib, a Btk inhibitor. Our results highlight the role of Cortactin in CLL as a check‐point molecule between the BCR and CXCR4 signalling pathways.
- 1 April 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (4) , 326-330
The molecular landscape of colitis-associated carcinogenesis
- 1 April 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (4) , 326-330
The molecular landscape of colitis-associated carcinogenesis
- 30 March 2017
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (7) , 860-862
Pigmented trichoblastoma developed in a sebaceous nevus: HRAS mutation as a common molecular driver
- 30 March 2017
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (7) , 860-862
Pigmented trichoblastoma developed in a sebaceous nevus: HRAS mutation as a common molecular driver
- 1 March 2017
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 39 (3) , e38-e40
Extraskeletal Myxoid Chondrosarcoma of the Foot Clinically Mimicking Plantar Fibromatosis
Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft tissue sarcoma usually presenting in proximal extremities of middle-aged men. The authors discuss a unique case of EMC, localized in the plantar foot of a 76-year-old woman, clinically suspected as plantar fibromatosis. It is important to avoid misdiagnosis of EMC because of their propensity for late recurrence and their metastatic potential.
- 1 March 2017
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 39 (3) , e38-e40
Extraskeletal Myxoid Chondrosarcoma of the Foot Clinically Mimicking Plantar Fibromatosis
Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft tissue sarcoma usually presenting in proximal extremities of middle-aged men. The authors discuss a unique case of EMC, localized in the plantar foot of a 76-year-old woman, clinically suspected as plantar fibromatosis. It is important to avoid misdiagnosis of EMC because of their propensity for late recurrence and their metastatic potential.
- 26 February 2017
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 147 (3) , 301-308
Early miR-223 Upregulation in Gastroesophageal Carcinogenesis
Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P < .001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P < .001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.
- 26 February 2017
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 147 (3) , 301-308
Early miR-223 Upregulation in Gastroesophageal Carcinogenesis
Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P < .001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P < .001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.